Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
CAS Number:
[1229022-83-6]
Target:
IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
